Will Biosimilars Impact the Cost of Specialty Drugs?

Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses whether the R&D cost for biosimilars will affect the overall cost reduction.

Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses whether the R&D cost for biosimilars will affect the overall cost reduction.